DelveInsight Blogs Sitemap

All Posts in this category
S.No. Product Name Actions
1 Roche inks $3B deal; Owlstone raises $58M; FDA approves OCS heart system; Google, Mayo Clinic build brain-mapping AI algorithm Visit Post
2 Abiomed’s Impella ECP; Helius’s PoNS Device; Smart Meter’s iGlucose BGM; XACT’s CT-Guided Percutaneous Procedures; BD’s Veritor At-Home COVID-19 Test; Delfi’s Liquid Biopsy Visit Post
3 Venous Thromboembolism Market Growth Quadrant to Balloon Up Visit Post
4 Boston Scientific’s EkoSonic; FDA clearance for EXALT; Kestra Medical’s ASSURE; ZOLL Next-Generation remedē system; CytoSorbents' DrugSorb-ATR; Fujifilm-Lunit collaboration Visit Post
5 New Approaches and Evolutions to Reshape the Diabetes Management and Care Visit Post
6 Nevro's Spinal Cord Stimulation; Boston's PINNACLE FLX; NuVasive's Modulus ALIF; J&J's VERITAS Vision System; Medtronic's DCB Catheter; AngelMed's Heart Attack Warning System Visit Post
7 With advancements in Innovative Technology, Cardiac Monitoring Devices Market is Booming Significantly Visit Post
8 MedTech Market Industry: Approval of Devices, Therapy Address Market Needs | Clinical Outcomes Create New Value Visit Post
9 Intellia's Quest with CRISPR; Innovent, Synaffix ADC Tech Deal; Lilly's Diabetes Blockbuster Tirzepatide; Polyphor’s Bleak Future Visit Post
10 What Factors are Shaping the Trends in the Implantable Cardiac Monitors Market? Visit Post
11 Insilico Medicine raises $255M; Sanofi & Translate Bio initiate trial; Medtronic gains expanded FDA approval; Blackstone, Cellex & Intellia form CAR-T startup Visit Post
12 Mallinckrodt earns FDA nod for skin therapy; RayzeBio secures $108M; VectorY raises $38M; Umoja banks $210M Visit Post
13 Eclipse, Medtronic, Aethlon, Cognoa, ObvioHealth, and others Continue to Veer MedTech Market Forward Visit Post
14 Medical Devices Market Blooms as the Key MedTech Companies Continue to Bring-In Innovation Visit Post
15 Continuous R&D Ramps Up the Pacemakers Pipeline Landscape, New Devices To Enter the Market Soon Visit Post
16 MedTech Industry Roars Back as FDA Approvals Soar Visit Post
17 Arch Oncology scores $105M; Abbott’s new coronary imaging platform; Lilly scraps IL-23 psoriasis program; Biogen offer access to experimental ALS med Visit Post
18 Ever-Evolving Market Landscape of Transcatheter Aortic Valve Replacement Visit Post
19 How Fitness Trackers Are Shaping the Future of Healthcare? Visit Post
20 Navigating Through the Treatment Market Landscape of Head and Neck Cancers Visit Post
21 Diagnosing At-Home: Are At-Home Diagnostic Tools The New Trends? Visit Post
22 Healthcare in 2021: Top Disruptions Bound To Impact The Way Healthcare Is Delivered Visit Post
23 The Mesh of the Generics and the Potential of Emerging Therapies in the Smoking Cessation Market Visit Post
24 Gilead and Vir collaborate; Tessera scores $230M; Teladoc & Dexcom bring CGM Tech; Verve unveils lead candidate Visit Post
25 Medical Tourism: Road to Affordable and Quality Medical Care Visit Post
26 Pfizer/ OPKO Health’s Somatrogon; FDA EU for SCONE device; Antengene ATG-010 for rrMM and rrDLBCL; SanBio STEMTRA Phase 2 Interim Results Visit Post
27 Top 10 Most Promising Drugs In The Amyotrophic Lateral Sclerosis Treatment Landscape Visit Post
28 Treating Patients with Software: Digital Therapeutics Visit Post
29 Will Wearable Devices be Streamlined in Healthcare? Visit Post
30 Creating Future of MedTech Industry with Artificial Intelligence Visit Post
31 The State of Alternative Medicine In The Healthcare Visit Post
32 Healthcare Delivery System: What lies in the future? Visit Post
33 Boehringer Ingelheim; Roche demonstrated new analyses of their drugs in patients with ILDs during the American Thoracic Society (ATS) Virtual conference Visit Post
34 Rejections and Withdrawals: Familial Chylomicronemia Syndrome Market Needs a Therapy Effective Enough, Affordable Enough Visit Post
35 Olema raises $54M; T3 Pharma bags $27M to advance bacterial cancer therapy program; Biofourmis and Chugai's Collaboration; A new study on averting heart attack Visit Post
36 What are the Top Five Leading Causes of Deaths in the World? Visit Post
37 With the Advances in Regenerative Therapy to Offer Curated Treatment Options, Off-label Therapy Market is Set to Decline for Dilated Cardiomyopathy Visit Post
38 Precision Medicine: An emerging approach to conventional treatment Visit Post
39 Mavacamten Phase III clinical trial, FDA nod for Ovarian cancer therapy, Dyno Therapeutics & Novartis Collaboration, Abbott's COVID-19 diagnostic kit Visit Post
40 Telemedicine: Can it be the future of healthcare? Visit Post
41 Ofev’s expanded use; Arkin Bio-Ventures II launch; USD 125 M for COVID-19 treatment Visit Post
42 Top healthcare innovations changing the healthcare dynamics Visit Post
43 Booming Healthcare sector in MENA: Lucrative opportunity for Global pharma players Visit Post
44 Cardiovascular Disease: A major cause of health loss and a global burden Visit Post
45 Potential of Digital therapeutics and increasing CVDs Visit Post
46 Acceleron Pharma's drug sotatercept touches the phase 2 mark; GT Medical receives nod for GammaTile; New treatment strategy for Parkinson's disease Visit Post
47 Tepezza receives approval; a new way to treat Alzheimer’s Visit Post
48 Polypills: Can they offer a potential approach to treat CVDs? Visit Post
49 Reversing Ischemia with Gene therapy Visit Post
50 FDA approval to AZ’s Farxiga for heart failure; GSK divests two travel vaccines to Bavarian Nordic; New breakthrough therapy for Cystic Fibrosis Visit Post
51 FDA approves Ofev for interstitial lung disease Visit Post
52 Helsinn out licenses Pracinostat in South America Visit Post
53 Juvenescence nets USD 100M; Sarepta DMD drug faces rejection Visit Post
54 Recursion Pharmaceuticals nets USD 121M; Bayer's MRI agent gets a nod Visit Post
55 Pulmonary Arterial Hypertension Therapies Visit Post
56 World Hypertension day Visit Post
57 Notizia Visit Post
58 Approach for Cystic Fibrosis; An alternative for Statins; Oral medications not safe; Carbon monoxide poisoning treatment gets approval Visit Post
59 Sage’s drug meets phase 3; Blocking 2 key pathways help in tackling TNBC; FDA clears Paragonix; FDA gives a nod Visit Post
60 Notizia Visit Post
61 WORLD HEART DAY | 29-09-2018 Visit Post
62 Notizia Visit Post
63 Notizia Visit Post
64 Commercial Visit Post
65 Key Clinical Outcomes- 30/07/2018 Visit Post
66 NF-κB Inhibitors- A Promising Future Visit Post
67 Cholesterol drug Praluent successful in reducing heart risk Visit Post
68 December 7 Business Cocktail Visit Post
69 Chemists may help solve the air-pollution health crisis Visit Post
70 AstraZeneca and Incyte Collaborate; Tocagen’s therapy; FDA warns companies;FDA Revokes Visit Post
71 Novo petitions FDA;J&J invests; Xarelto’s trial; Roche's Tecentriq Visit Post
72 Thrombolytic Sciences’ trial; NurOwn for ALS; Biosimilar receives approval; Trelegy Ellipta for the treatment of COPD Visit Post
73 Cannabidiol trial; MyoKardia aims; LDL drug data Visit Post
74 Sanofi invests; ICER pitches; $6M in NIH; Pfizer, Roche cancer drug pricing Visit Post
75 Lilly moves ahead; Authorities raid; Bristol-Myers, AZ in legal; PhRMA expected to weed out Visit Post
76 Merck’s Keytruda sales; Valeant on name change; Pfizer – BMS; Amgen puts Repatha outcomes for deal Visit Post
77 Medical tourism in India Visit Post
78 AMRI enters alliance; Ferring and Enteris deal; Quotient Clinical Acquires; Renova takes over Rights Visit Post
79 mTOR Inhibitors-Emerging therapy in various therapeutic areas Visit Post
80 Sanofi, Regeneron one step closer; Pharma's deal; J&J and Actelion deal Visit Post
81 Angina Pectoris : Manifestation of Coronary Artery Disease Visit Post
82 Glaxo replaces ViiV; Lilly nets; AstraZeneca shuffles off; Gazyva aims to beat Visit Post
83 Neprilysin Inhibitor for Cardiovascular Diseases Visit Post
84 Sun Pharma Announces Launch; OptiNose files; Opiant obtains rights; Swissmedic approves Visit Post
85 Bayer Partners with DelSiTech to Develop; Amgen and Arrowhead Announce; Allergan, AstraZeneca’s deal; Lexicon Pharma announces deal Visit Post
86 Sun Pharma forms partnership; Pfizer and DCRI collaborate; Avara Acquires AZ; ASLAN Pharmaceutical’s Collaboration; Amgen and Servier partnership Visit Post
87 Anticoagulants (VTE & AF) Therapeutics Market Visit Post
88 Global atrial fibrillation market is expected to grow to $12.5 billion by 2020 Visit Post
89 Global VTE market is expected to grow to $4.75 billion by 2020 Visit Post
90 Anticoagulants-Market Insights; Drugs Sales Forecast (VTE & AF) Visit Post
91 New Approach Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Visit Post
92 DelveInsight launches Indication Active Pharmaceutical Ingredient (API) Reports Visit Post
93 Outbreak of Companies Challenging New Pathways for Treatment of Pulmonary Arterial Hypertension Visit Post
94 DelveInsight’s Cardiovascular disorders based Gene Therapy Reports Visit Post